Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Annals of the Rheumatic Diseases

Op0212 Highdose Chemotherapy and Transplantation of 34+ Selected Stem Cells for Progressive Systemic Sclerosis With or Without Cardiac Involvement or Alveolitis - Modification According to Manifestation (Ast Moma)

View Full Paper
Ask AI
Bookmark
Share

Authors

APAnn‐Christin PecherUniversity Children's Hospital TübingenIKIna KötterEppendorf (Germany)RKReinhild KleinSTZ eyetrial

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pecher et al. (2024) studied this question.

synapsesocial.com/papers/68e671b1b6db6435875fbb7chttps://doi.org/10.1136/annrheumdis-2024-eular.1742
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adopting a Standard of Care for Systemic Sclerosis: The Mayo Clinic Experience2026
  2. 2High-dose chemotherapy and transplantation of autologous CD34+ selected stem cells for progressive systemic sclerosis adjusted to cardiac and lung manifestation: an open-label, non-inferiority phase 2 trial2026
  3. 3High-dose chemotherapy and autologous hematopoietic stem cell transplantation for progressive systemic sclerosis: a retrospective study of outcome and prognostic factors2024 · 6 citations
  4. 4POS0819 ANTI-CD19 CAR T CELL THERAPY IN SYSTEMIC SCLEROSIS – EXPERIENCES FROM TUEBINGEN IN 3 PATIENTS2024 · 4 citations
  5. 5Australian rheumatologists' perception of autologous haemopoietic stem cell transplantation for the treatment of systemic sclerosis: a cross‐sectional survey2024 · 1 citations